Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Human papilloma virus vaccination and its real-life efficacy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Current use of noninvasive prenatal testing in Europe, Australia and the USA: A graphical presentation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Implementation of exome sequencing in fetal diagnostics - data and experiences from a tertiary center in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. "It's probably nothing, but…" Couples' experiences of pregnancy following an uncertain prenatal genetic result

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Non-invasive prenatal testing and maternal obesity - A review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. MicroRNA Biomarkers in IBD-Differential Diagnosis and Prediction of Colitis-Associated Cancer

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Menstrual Pattern, Reproductive Hormones and Transabdominal 3D Ultrasound in 317 Adolescent Girls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Abstract  Objective. Risk of malignancy index (RMI), based on a serum cancer antigen 125 level, ultrasound findings and menopausal status, is used to discriminate ovarian cancer from benign pelvic mass. In Denmark, patients with pelvic mass and RMI ≥200 are referred to tertiary gynecologic oncology centers according to the national guidelines for ovarian cancer treatment. The guidelines include recalculation of RMI at the tertiary center and, if indicated, positron emission tomography/computed tomography and fast-track surgery by specialists in cancer surgery. The aim of this study was to validate the use of RMI ≥200 as a tool for preoperative identification of ovarian cancer at a tertiary center. Design. Prospective observational study. Setting. A tertiary center in Copenhagen, Denmark. Population. One thousand one hundred and fifty-nine women with pelvic mass. Methods. The RMI was calculated after ultrasound examination and blood sampling for serum cancer antigen 125 analysis within two weeks before surgery. Main outcome measures. Sensitivity, specificity, positive and negative predictive values were calculated to evaluate the ability of RMI to distinguish between ovarian cancer and benign pelvic mass. Results. There were 778 women diagnosed with benign pelvic mass, while 251 had ovarian cancer and 74 had borderline ovarian tumor. Fifty-six women were diagnosed with other forms of cancer. Sensitivity and specificity for ovarian cancer vs. benign pelvic mass for RMI ≥200 were 92 and 82%, respectively. Corresponding positive and negative predictive values were 62 and 97%. Conclusions. Risk of malignancy index ≥200 is a reliable tool for identifying patients with ovarian cancer pelvic masses at a tertiary centre to select patients for further preoperative examinations.
OriginalsprogEngelsk
TidsskriftActa Obstetricia et Gynecologica Scandinavica
Vol/bind91
Udgave nummer4
Sider (fra-til)496-502
ISSN0001-6349
DOI
StatusUdgivet - 2012

ID: 34668759